Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin A Katzman

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
CNS Drugs|January 29, 2009
Current considerations in the treatment of generalized anxiety disorderMartin A Katzman
Psychiatry Research|December 26, 2014
Managing major depressive disorder through the use of adjunct therapiesMartin A Katzman
Journal of Affective Disorders|January 12, 2011
Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illnessMartin A Katzman
Psychiatry Research|July 19, 2015
Examining the role of neuroinflammation in major depressionMelissa Furtado, Martin A Katzman
CNS Drugs|August 15, 2014
A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorderMartin A Katzman, Tia Sternat
Paediatrics & Child Health|August 15, 2009
Behavioural inhibition: A predictor of anxietyMartin Svihra, Martin A Katzman
Neuropsychiatric Disease and Treatment|March 21, 2009
Venlafaxine in the treatment of panic disorderMartin A Katzman, Leslie Jacobs
Psychiatry Research|August 23, 2015
Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disordersMelissa Furtado, Martin A Katzman
Neuropsychiatric Disease and Treatment|September 8, 2016
Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuseTia Sternat, Martin A Katzman
Evidence-Based Mental Health|April 20, 2011
Review: reboxetine is ineffective and potentially harmful for acute treatment of major depressionMartin A Katzman, Dina Tsirgielis
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
CNS Drugs|January 29, 2009
Current considerations in the treatment of generalized anxiety disorderMartin A Katzman
Psychiatry Research|December 26, 2014
Managing major depressive disorder through the use of adjunct therapiesMartin A Katzman
Journal of Affective Disorders|January 12, 2011
Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illnessMartin A Katzman
Psychiatry Research|July 19, 2015
Examining the role of neuroinflammation in major depressionMelissa Furtado, Martin A Katzman
CNS Drugs|August 15, 2014
A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorderMartin A Katzman, Tia Sternat
Paediatrics & Child Health|August 15, 2009
Behavioural inhibition: A predictor of anxietyMartin Svihra, Martin A Katzman
Neuropsychiatric Disease and Treatment|March 21, 2009
Venlafaxine in the treatment of panic disorderMartin A Katzman, Leslie Jacobs
Psychiatry Research|August 23, 2015
Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disordersMelissa Furtado, Martin A Katzman
Neuropsychiatric Disease and Treatment|September 8, 2016
Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuseTia Sternat, Martin A Katzman
Evidence-Based Mental Health|April 20, 2011
Review: reboxetine is ineffective and potentially harmful for acute treatment of major depressionMartin A Katzman, Dina Tsirgielis
Pageof 7